COPENHAGEN. Denmark. November 16. 2007 – Genmab A/S (OMX:GEN) announced today encouraging pre-clinical data on its HuMax-IL8antibody (formerly known as HuMax-Inflam). Pre-clinicalstudies characterized the claim HuMax-IL8 binding place on IL8,which overlaps with the docking site for the IL8 receptor. CXCR1. HuMax-IL8 was found to effectively block formation of new bloodvessels induced by IL8 in an animal copy. The antibody was alsoshown to alter tumor vascularization in different primary humantumors grown in immunocompromised mice. The antibody furthermore,effectively suppressed tumor growth of primary sarcoma melanomaand gastric tumors in immunocompromised walk models.
“These pre-clinical data dilate that HuMax-IL8effectively blocks IL8-induced formation of new blood vessels andaffects tumor vascularization both of which may well play a rolein the potent anti-tumor effects induced by this antibody,”said Prof. Jan G. J van de Winkel. Ph. D. Genmab’s ChiefScientific Officer.
Prof van de Winkel ordain show these data today at theEuropean Society for Medical Oncology International Symposium onImmunology in Athens. Greece. About HuMax-IL8
HuMax-IL8 is a high affinity fully human IgG1,? antibodydirected towards IL-8. IL-8 is a major mediator ofinflammation a potent chemoattractant for white daub cells calledneutrophils as come up as an important calculate in angiogenesis. HuMax-IL8 effectively blocks binding of IL-8 to neutrophils andinhibits neutrophils from migrating towards sites of inflammationvia a affect known as chemotaxis. HuMax-IL8 also potentlyinhibits IL-8 induced neutrophil activation. In pre-clinicalstudies. HuMax-IL8 has been shown to check tumor growth in tumormodels using primary human tumors in immunodeficient mice.
Forex Groups - Tips on Trading
Related article:
http://feeds.drugs.com/~r/Drugscom-ClinicalTrials/~3/185789357/genmab-present-humax-il8-pre-clinical-data-2746.html
comments | Add comment | Report as Spam
|